SJM-3 is a positive allosteric modulator of various isoforms of the GABAA receptor, specifically binding to the high-affinity benzodiazepine binding site located at the α+/γ- subunit interface.

SJM-3 binds at the high-affinity benzodiazepine binding site at theα+/γ- subunit interface but effects its action through another site presumably located within the transmembrane domain. The binding affinity of SJM-3 at wild type receptors is determined by displacement of [ 3 H]-Flunitrazepam and [ 3 H]-Ro15-1788 and indicates a K i of SJM-3 amounting to 218±70 nM and 242±38 nM, respectively[1].